Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Pfizer1,723 enrolled

Overview

This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension

Non Probability Sampling

Study Type

OBSERVATIONAL

Enrollment

1,723

Conditions

Hypertension

Interventions

Olmesartan medoxomilDRUG

olmesartan medoxomil 20 mg and HCTZ 12.5 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and Female patients 18 to 65 y/old * Patient previously taking low-dose medoxomil or any other ARB alone with uncontrolled BP * Patient with uncontrolled mild to moderate hypertension (SBP\>= 140 and \<=179 mmHg OR DBP of \>=90 and \<=109 mmHg) Exclusion Criteria: * Pregnant of Lactating women * History of secondary hypertension

Outcomes

Primary Outcomes

Safety (Adverse Events)

Time frame: 4 weeks

Secondary Outcomes

Blood Pressure

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.